4001. Advancing Cardiovascular Care From Diagnosis to Therapy

Industry-Expert Theater 1, #2263
Sponsored by Abbott

4009. Breaking Barriers: Tackling Uncontrolled and Resistant Hypertension - The Symplicity™ Blood Pressure Procedure

Industry-Expert Theater 2, #2562
Sponsored by Medtronic

Unlock New Possibilities For Your Hypertension Patients! Join us for an engaging session featuring leading experts as we explore cutting-edge complementary treatment options for managing hypertension. What to Expect:

• Expert Presentations: Gain insights from top professionals in the field.
• Interactive Discussions: Dive deep into the latest guidelines and clinical evidence.
• Real-World Applications: Learn about patient selection, shared decision-making, and compelling case studies on renal denervation.
• Don't miss this opportunity to enhance your practice and improve patient outcomes. Together, we can pave the way for innovative hypertension care!

Secure your spot today and be part of the conversation!

Speakers:

Tiffany C. Randolph, MD
Cone Health
Greensboro, NC

Yvonne Commodore-Mensah, PhD, MHS, BSN, RN, FAAN, FAHA, FPCNA
Johns Hopkins
Baltimore, MD

Michael J. Bloch, MD
Renown Health
Reno, NV

Jeremy S. Bock, MD, FACC, FSCAI
Virginia Heart
Leesburg, VA

Supreeti Behuria, MD
Northwell Health
Staten Island, NY

4017. Introduction to AMVUTTRA® (vutrisiran)

Industry-Expert Theater 3, #2863
Sponsored by Alnylam Pharmaceuticals

Join our distinguished faculty as they review the clinical profile of AMVUTTRA for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Speaker:

Saurabh Malhotra, MD, MPH, FACC, FASNC
Associate Professor of Medicine and Director of Advanced Cardiac Imaging and Cardiac Stress Testing Laboratory
Cook County Health

4002. Make It Standard: Lp(a) Integration For CV Risk Impact

Industry-Expert Theater 1, #2263
Sponsored by Novartis Pharmaceuticals

A disease state (non-CME), presentation by leading medical experts, including a unique patient perspective from someone diagnosed with elevated Lp(a). This program will focus on the relationship between elevated Lp(a) and premature CAD, as well as the clinical implications of Lp(a) elevation post-ACS.

4010. A New Option For Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM)

Industry-Expert Theater 2, #2562
Sponsored by Cytokinetics

4018. Title to be Announced

Industry-Expert Theater 3, #2863
Sponsored by Bristol Myers Squibb

4003. Implementation in Action: Closing the Gap in ASCVD

Industry-Expert Theater 1, #2263
Sponsored by Amgen

4011. Health Disparities in hATTR

Industry-Expert Theater 2, #2562
Sponsored by AstraZeneca

4019.

Industry-Expert Theater 3, #2863
Sponsored by Merck

4004. From Suspicion to Strategy: Contemporary ATTR-CM Management in Clinical Practice

Industry-Expert Theater 1, #2263
Sponsored by Pfizer

This session reviews the essential role of the cardiologist in identifying, diagnosing, and managing transthyretin cardiac amyloidosis (ATTR-CM). Through a patient case study and expert perspectives, the program will review contemporary clinical approaches. Data on an oral therapeutic option, including long-term extension and real-world evidence will be presented. The session will also summarize recently published consensus recommendations for monitoring disease progression.

4012. Title to be Announced

Industry-Expert Theater 2, #2562
Sponsored by Novartis Pharmaceuticals

4020. TRYNGOLZA: Designated a Breakthrough Therapy For the Treatment of Familial Chylomicronemia Syndrome (FCS)

Industry-Expert Theater 3, #2863
Sponsored by Ionis Pharmaceuticals, Inc.

4005. Cardiovascular Outcomes in Patients at High CV Risk: Evidence From the VESALIUS-CV Study

Industry-Expert Theater 1, #2263
Sponsored by Amgen

4013. Unlocking CV Inflammation in Clinical Practice

Industry-Expert Theater 2, #2562
Sponsored by Novo Nordisk

4021.

Industry-Expert Theater 3, #2863
Sponsored by Kiniksa Pharmaceuticals

4006. CHAMPION Insights: Advancing Stroke Protection in AF Management

Industry-Expert Theater 1, #2263
Sponsored by Boston Scientific

4014. Elevated Lp(a): Implications For Patient Risk Assessment

Industry-Expert Theater 2, #2562
Sponsored by Amgen

4022. Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist

Industry-Expert Theater 3, #2863
Sponsored by Eli Lilly & Company

Learn about tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, the active ingredient in Zepbound® (tirzepatide) and Mounjaro® (tirzepatide). In this program, we will review clinical efficacy, safety, and dosing and administration information about Zepbound and Mounjaro. Attendees will have the opportunity to ask questions to the speaker at the conclusion of the program.

Please see the Important Safety Information for Zepbound, including Boxed Warning, the full Prescribing Information, and Medication Guide provided at the product theater and available on www.zepbound.lilly.com/hcp. Please see the Important Safety Information for Mounjaro, including Boxed Warning, the full Prescribing Information, and Medication Guide provided at the product theater and available on www.mounjaro.lilly.com/hcp. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. Mounjaro® and Zepbound® and their delivery device bases are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC.

Speaker:

Alicia Shelly, MD, FACP, DABOM

4007. Cracking the Code: Uncover a Hidden Driver of Resistant Hypertension

Industry-Expert Theater 1, #2263
Sponsored by Corcept Therapeutics

Join us as leading experts uncover the role of hypercortisolism as a hidden driver of resistant hypertension and share their clinical insights to help identify this often-overlooked contributor

4015.

Industry-Expert Theater 2, #2562
Sponsored by Novo Nordisk

4023. Cracking the Code: Managing Hypercortisolism-Driven Resistant Hypertension in the Modern Era

Industry-Expert Theater 3, #2863
Sponsored by Corcept Therapeutics

Resistant hypertension remains a significant clinical challenge, affecting a substantial proportion of patients despite the availability of multiple antihypertensive therapies. Emerging evidence highlights hypercortisolism—both overt and subclinical—as an underrecognized and potentially reversible cause of resistant hypertension. However, the nonspecific presentation of hypercortisolism and the overlap with other comorbidities often delay diagnosis and effective treatment. Join us for this live educational activity that will enhance your clinical knowledge, competence, and confidence in identifying and managing hypercortisolism in the context of resistant hypertension. The panel of experts will present the latest clinical data and emerging treatments through an engaging case-based format. They will highlight new findings, including recent advances with selective cortisol receptor modulators.

Speakers:

Deepak L. Bhatt, MD, MPH, MBA
Director, Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Richard J. Auchus, MD, PhD, FACE
The James A. Shayman and Andrea S. Kevrick Professor of Translational Medicine
Division of Metabolism, Endocrinology and Diabetes
Departments of Internal Medicine and Pharmacology
University of Michigan Medical School
Ann Arbor, Michigan

Raymond R. Townsend, MD, FAHA
Professor Clinician Educator of Medicine
Department of Internal Medicine/Renal
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

4008. AFib and Stroke Protection: Contemporary Management, Trials, and Practice Integration

Industry-Expert Theater 1, #2263
Sponsored by Boston Scientific

4016.

Industry-Expert Theater 2, #2562
Sponsored by GE Healthcare

4024.

Industry-Expert Theater 3, #2863
Sponsored by Milestone Pharmaceuticals

Speaker:

Farhad Rafii, MD